SK285330B6 - Použitie formoterolu a budesonidu na výrobu farmaceutického prostriedku na liečbu chronickej obštrukčnej pľúcnej choroby - Google Patents

Použitie formoterolu a budesonidu na výrobu farmaceutického prostriedku na liečbu chronickej obštrukčnej pľúcnej choroby Download PDF

Info

Publication number
SK285330B6
SK285330B6 SK389-2000A SK3892000A SK285330B6 SK 285330 B6 SK285330 B6 SK 285330B6 SK 3892000 A SK3892000 A SK 3892000A SK 285330 B6 SK285330 B6 SK 285330B6
Authority
SK
Slovakia
Prior art keywords
active ingredient
budesonide
formoterol
obstructive pulmonary
pulmonary disease
Prior art date
Application number
SK389-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK3892000A3 (en
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285330(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK3892000A3 publication Critical patent/SK3892000A3/sk
Publication of SK285330B6 publication Critical patent/SK285330B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK389-2000A 1997-09-19 1998-09-09 Použitie formoterolu a budesonidu na výrobu farmaceutického prostriedku na liečbu chronickej obštrukčnej pľúcnej choroby SK285330B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use
PCT/SE1998/001599 WO1999015182A1 (en) 1997-09-19 1998-09-09 New use for budesonide and formoterol

Publications (2)

Publication Number Publication Date
SK3892000A3 SK3892000A3 (en) 2000-12-11
SK285330B6 true SK285330B6 (sk) 2006-11-03

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
SK389-2000A SK285330B6 (sk) 1997-09-19 1998-09-09 Použitie formoterolu a budesonidu na výrobu farmaceutického prostriedku na liečbu chronickej obštrukčnej pľúcnej choroby

Country Status (38)

Country Link
US (2) US7897646B2 (de)
EP (2) EP1210943B1 (de)
JP (1) JP2001517630A (de)
KR (1) KR20010024140A (de)
CN (1) CN1149998C (de)
AR (1) AR013506A1 (de)
AT (2) ATE222106T1 (de)
AU (1) AU757235B2 (de)
BR (1) BR9812325A (de)
CA (1) CA2302700C (de)
CY (1) CY1106156T1 (de)
CZ (1) CZ295250B6 (de)
DE (2) DE69834955T2 (de)
DK (2) DK1014993T3 (de)
EE (1) EE04297B1 (de)
ES (2) ES2182357T3 (de)
HK (1) HK1045812B (de)
HU (1) HUP0003848A2 (de)
ID (1) ID24838A (de)
IL (1) IL134773A (de)
IN (1) IN190791B (de)
IS (1) IS2715B (de)
MX (1) MXPA00002615A (de)
MY (1) MY127812A (de)
NO (1) NO327176B1 (de)
NZ (1) NZ503173A (de)
PL (1) PL190782B1 (de)
PT (2) PT1014993E (de)
RU (1) RU2199322C2 (de)
SA (1) SA98190773B1 (de)
SE (1) SE9703407D0 (de)
SI (2) SI1210943T1 (de)
SK (1) SK285330B6 (de)
TR (1) TR200000726T2 (de)
TW (1) TW546140B (de)
UA (1) UA72446C2 (de)
WO (1) WO1999015182A1 (de)
ZA (1) ZA988516B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
WO2002062317A2 (en) * 2001-02-06 2002-08-15 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US20040105821A1 (en) * 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ATE552032T1 (de) * 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
SG182485A1 (en) * 2010-01-15 2012-08-30 Lithera Inc Lyophilized cake formulations
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
AU2019287541A1 (en) 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
US5250286A (en) 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1086697A2 (de) 1991-12-18 2001-03-28 AstraZeneca AB Neue Verwendung von Budesonide und Formoterol
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
IL124522A0 (en) * 1995-11-24 1998-12-06 Smithkline Beecham Spa Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
TR199903272T2 (xx) 1997-06-27 2000-08-21 Astra Aktiebolag Ast�m kar��t� ila�lar�n yeni bile�imleri.
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
ATE329599T1 (de) 2006-07-15
CN1271287A (zh) 2000-10-25
DE69807239D1 (de) 2002-09-19
EP1210943B1 (de) 2006-06-14
JP2001517630A (ja) 2001-10-09
NZ503173A (en) 2001-08-31
ZA988516B (en) 1999-03-19
IL134773A0 (en) 2001-04-30
WO1999015182A1 (en) 1999-04-01
US20060189587A9 (en) 2006-08-24
US20110097282A1 (en) 2011-04-28
IL134773A (en) 2005-03-20
AR013506A1 (es) 2000-12-27
DE69807239T2 (de) 2003-04-10
SI1014993T1 (en) 2003-02-28
IN190791B (de) 2003-08-23
CY1106156T1 (el) 2011-06-08
EE04297B1 (et) 2004-06-15
PT1210943E (pt) 2006-09-29
CA2302700A1 (en) 1999-04-01
NO20001401D0 (no) 2000-03-17
US8461211B2 (en) 2013-06-11
EE200000145A (et) 2001-02-15
EP1014993A1 (de) 2000-07-05
CZ295250B6 (cs) 2005-06-15
AU9192898A (en) 1999-04-12
BR9812325A (pt) 2000-09-05
US20020042404A1 (en) 2002-04-11
DK1014993T3 (da) 2002-11-11
CN1149998C (zh) 2004-05-19
ID24838A (id) 2000-08-24
IS2715B (is) 2011-02-15
PL190782B1 (pl) 2006-01-31
DK1210943T3 (da) 2006-09-18
DE69834955D1 (de) 2006-07-27
HK1045812B (zh) 2006-12-22
PT1014993E (pt) 2002-12-31
NO327176B1 (no) 2009-05-04
US7897646B2 (en) 2011-03-01
TW546140B (en) 2003-08-11
MXPA00002615A (es) 2002-04-24
PL339295A1 (en) 2000-12-04
SE9703407D0 (sv) 1997-09-19
ES2266322T3 (es) 2007-03-01
DE69834955T2 (de) 2007-01-25
EP1014993B1 (de) 2002-08-14
SA98190773B1 (ar) 2006-10-02
CZ2000950A3 (cs) 2000-06-14
SK3892000A3 (en) 2000-12-11
IS5407A (is) 2000-03-15
MY127812A (en) 2006-12-29
UA72446C2 (uk) 2005-03-15
TR200000726T2 (tr) 2000-09-21
SI1210943T1 (sl) 2006-10-31
HK1045812A1 (en) 2002-12-13
CA2302700C (en) 2010-11-23
NO20001401L (no) 2000-03-17
AU757235B2 (en) 2003-02-06
EP1210943A1 (de) 2002-06-05
ATE222106T1 (de) 2002-08-15
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
ES2182357T3 (es) 2003-03-01
HUP0003848A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
SK285330B6 (sk) Použitie formoterolu a budesonidu na výrobu farmaceutického prostriedku na liečbu chronickej obštrukčnej pľúcnej choroby
AU715319B2 (en) New combination
KR100234864B1 (ko) 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
JP2002517450A (ja) 喘息の急性状態の予防または処置のための、ホルモテロールおよびブデソニドを含んでなる組成物の使用
CA2388657A1 (en) New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist
AU8135098A (en) New combination of antiasthma medicaments
AU766637B2 (en) New use for budesonide and formoterol

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20160909

MC4A Annulment of patent

Effective date: 20170721